Background Prevalence and risk factors for respiratory symptoms and airway obstruction in HIV-infected subjects in the era of highly active antiretroviral therapy (HAART) are unknown. We evaluated respiratory symptoms and measured airway obstruction to identify the impact of HAART and other risk factors on respiratory symptoms and pulmonary function. Methodology/Principal Findings Two hundred thirty-four HIV-infected adults without acute respiratory symptoms were recruited from an HIV clinic. All subjects were interviewed and performed spirometry. Multivariate linear and logistic regressions were performed to determine predictors of respiratory symptoms, forced expiratory volume in one second (FEV1) percent predicted, and FEV1/forced vital capacity (FEV1/FVC). Thirty-one percent of subjects reported at least one respiratory symptom. Smoking status (current or former versus never) (odds ratio [OR] = 2.7, 95% confidence interval [CI] = 1.41–5.22, p = 0.003), higher log plasma HIV viral levels (OR = 1.12, 95%CI = 1.02–1.24, p = 0.02), and lower FEV1/FVC (OR = 1.06 for every 0.01 decrease in FEV1/FVC, 95%CI = 1.02–1.14, p = 0.001) were independent predictors of respiratory symptoms. Age (p = 0.04), pack-year smoking history (p<0.001), previous bacterial pneumonia (p = 0.007), and HAART use (p = 0.04) were independent predictors of decreased FEV1/FVC. Conclusions/Significance Respiratory symptoms remain common in HIV-infected subjects, especially in those with a smoking history. Subjects who were older, had a greater pack-year history of smoking, or previous bacterial pneumonia had lower FEV1/FVC ratios. Interestingly, use of HAART was independently associated with a decreased FEV1/FVC, possibly secondary to an immune response to subclinical infections, increased autoimmunity, or other factors associated with HAART use.
References
[1]
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860.
[2]
Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. (2003) Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179–1193.
[3]
Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165: 1179–1184.
[4]
Lipman M, Breen R (2006) Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 19: 20–25.
[5]
Zandman-Goddard G, Shoenfeld Y (2002) HIV and autoimmunity. Autoimmun Rev 1: 329–337.
[6]
Diaz PT, Wewers MD, Pacht E, Drake J, Nagaraja HN, et al. (2003) Respiratory symptoms among HIV-seropositive individuals. Chest 123: 1977–1982.
[7]
Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, et al. (2000) Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 132: 369–372.
[8]
Rosen MJ, Lou Y, Kvale PA, Rao AV, Jordan MC, et al. (1995) Pulmonary function tests in HIV-infected patients without AIDS. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 152: 738–745.
[9]
Crothers K (2007) Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med 28: 575–587.
[10]
Mitchell DM, Fleming J, Pinching AJ, Harris JR, Moss FM, et al. (1992) Pulmonary function in human immunodeficiency virus infection. A prospective 18-month study of serial lung function in 474 patients. Am Rev Respir Dis 146: 745–751.
[11]
Morris AM, Huang L, Bacchetti P, Turner J, Hopewell PC, et al. (2000) Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 162: 612–616.
[12]
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) Standardisation of spirometry. Eur Respir J 26: 319–338.
[13]
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127: 725–734.
[14]
Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S (1997) A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 16: 965–980.
[15]
Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS (2001) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 163: 1256–1276.
[16]
Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173–1182.
[17]
Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, et al. (1997) Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 155: 72–80.
[18]
Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, et al. (1999) The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Am J Respir Crit Care Med 160: 272–277.
[19]
Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, et al. (2006) Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 130: 1326–1333.
[20]
Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, et al. (2005) Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine 84: 98–106.
[21]
Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, et al. (2000) Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 85: 4254–4257.
[22]
Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E (2002) Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 29: 441–449.
[23]
Mondal D, Pradhan L, Ali M, Agrawal KC (2004) HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 4: 287–302.
[24]
Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, et al. (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399–406.
[25]
Sethi S (2000) Bacterial infection and the pathogenesis of COPD. Chest 117: 286S–291S.
[26]
Sethi S (2004) Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc 1: 109–114.
[27]
Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, et al. (2001) Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 164: 469–473.
[28]
Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, et al. (2004) Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 170: 408–413.
[29]
Huang L, Crothers K, Morris A, Groner G, Fox M, et al. (2003) Pneumocystis colonization in HIV-infected patients. J Eukaryot Microbiol 50: Suppl616–617.
[30]
Calabrese LH, Kirchner E, Shrestha R (2005) Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 35: 166–174.
[31]
Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, et al. (2003) Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest 124: 929–935.
[32]
O'Leary JG, Zachary K, Misdraji J, Chung RT (2008) De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis 46: e12–14.
[33]
Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, et al. (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690–695.
Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch FM (1999) Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 15: 1499–1508.
[36]
de St Groth BF, Landay AL (2008) Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS 22: 671–683.
[37]
Epple HJ, Loddenkemper C, Kunkel D, Troger H, Maul J, et al. (2006) Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 108: 3072–3078.
[38]
Agusti A, MacNee W, Donaldson K, Cosio M (2003) Hypothesis: does COPD have an autoimmune component? Thorax 58: 832–834.
[39]
Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, et al. (2007) Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13: 567–569.
[40]
Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, et al. (2008) Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 156–163.
[41]
Wallace JM, Stone GS, Browdy BL, Tashkin DP, Hopewell PC, et al. (1997) Nonspecific airway hyperresponsiveness in HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 111: 121–127.
